The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of June 30, 2017:
- 42 negotiations are currently underway with 6 new files added since the last update of May 31, 2017:
- Caprelsa (vandetanib): Used to treat medullary thyroid cancer
- Kyprolis (carfilzomib): Used to treat multiple myeloma (relapsed)
- Narcan (naloxone hydrochloride): Used to treat opioid overdose
- Otezla (apremilast): Used to treat moderate to severe plaque psoriasis
- Revestive (teduglutide): Used to treat short bowel syndrome (SBS)
- Strensiq (asfotase alfa): Used to treat pediatric-onset hypophosphatasia
- 160 joint negotiations have been completed with 7 files successfully negotiated since the last update of May 31, 2017:
- Brenzys (etanercept): Used to treat rheumatoid arthritis and ankylosing spondylitis
- Imbruvica (ibrutinib): Used to treat relapsed/refractory Mantle Cell Lymphoma
- Imbruvica (ibrutinib): Used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma
- Lenvima (lenvatinib): Used to treat thyroid cancer
- Mozobil (plerixafor): Used in combination with granulocyte colony-stimulating factor to support treatment for non-Hodgkin lymphoma and multiple myeloma (second letter of intent)
- Neupro (rotigotine): Used to treat Parkinson’s disease
- XigDuo (dapagliflozin/metformin hydrochloride): Used to treat type 2 diabetes mellitus
- 50 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of May 31, 2017.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of May 31, 2017.
For more information, please consult the pCPA’s website.